These innovative agents represent a significant progression in the treatment of type 2 diabetes. Retatrutide, a dual GLP-1 and GIP receptor agonist, demonstrates exceptional efficacy in lowering blood glucose levels. https://berthagcup772511.blogdemls.com/38947057/novel-glp-1-receptor-agonists-retatrutide-and-trizepatide